The University of Texas System says UTSA researchers have a new peptide project tied to rising interest from the GLP-1 boom. Details on the research goals are at the link.
Recap by typeshit. Post by The University of Texas System on X.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Robert Lufkin MD shares the observational data: an average 16.1 kg lost at six months among 7,297 women, with 62.7% reporting side effects.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
14:11
Mike puts gray market peptides from Chinese sellers to the test. Tap through to see what he checks for and what he found.
Philstar Life pushes back on how Ozempic gets talked about, framing it as something other than a weight loss drug. Only the headline is available, so tap through for the argument.
Loading…